BioMarin Pharmaceutical Inc. research snapshot
BMRN AI stock analysis currently reads BioMarin Pharmaceutical Inc. as a commercial-stage rare-disease company with a durable enzyme and skeletal-growth portfolio, VOXZOGO franchise expansion, improving cash generation, and a newly closed $4.8 billion Amicus acquisition that adds GALAFOLD and POMBILITI + OPFOLDA while raising leverage. At the August 3, 2026 data cutoff, BMRN last closed near $60.02 on July 31, 2026, with an implied market capitalization of about $11.60 billion. Q2 2026 results are scheduled for August 6, 2026, after this cutoff. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$60.02
Market cap
$11.60 billion
AI score
67 / 100
Rating
Quality rare-disease franchise, integration-sensitive
Trend status
Constructive above rising moving averages, still below the $66.28 52-week high
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | BioMarin sells rare-disease medicines led by enzyme therapies and VOXZOGO, now expanded by Amicus products GALAFOLD and POMBILITI + OPFOLDA for Fabry and Pompe disease. | High |
| Moat | The moat comes from rare-disease IP, specialist relationships, regulatory barriers, manufacturing know-how, and multi-product commercial infrastructure across lysosomal and skeletal conditions, but it narrows as rivals such as Ascendis and BridgeBio target achondroplasia. | Medium-high |
| Management | CEO Alexander Hardy has driven portfolio focus, operating efficiency, and large M&A (Inozyme and Amicus), but capital allocation now rests on integration quality, leverage discipline, and pipeline execution for BMN 401, BMN 333, and BMN 351. | Medium-high |
| Financial trend | FY2025 revenue rose to $3.221 billion (+13% Y/Y), GAAP diluted EPS was $1.80, non-GAAP diluted EPS was $3.15, and FY2025 free cash flow was about $725 million. Q1 2026 revenue was $766 million with GAAP diluted EPS of $0.54 and non-GAAP diluted EPS of $0.76. | High |
| Valuation | At $60.02, BMRN traded near 12.1x the 2026 non-GAAP EPS guidance midpoint of $4.85 to $5.05, about 15.1x trailing free cash flow, about 3.6x trailing sales, and 42.9x trailing GAAP EPS. | Medium-high |
| Technical trend | Price sat above the rising 20, 50, 100, and 200-day moving averages near $56 to $60, with ChartMill support near $59.7 to $59.9 and resistance toward the $63 area and the $66.28 52-week high. | Medium |
| Risk level | Main risks are VOXZOGO competition, Amicus integration and debt service after about $3.7 billion of acquisition financing, product concentration, pipeline setbacks, and rare-disease pricing pressure. | Medium-high |
| AI confidence | High for descriptive research and calculations. Lower for exact price outcomes because biotech stocks move around competition, payer, regulatory, and integration news. | High data confidence |
| Investment certainty | Medium certainty. BioMarin has a valuable rare-disease commercial base, but the stock needs clean Amicus integration, durable VOXZOGO or enzyme growth, and Q2 2026 confirmation to justify a re-rating. | Medium |
BMRN AI stock forecast
The BMRN AI stock forecast uses scenario math around the $60.02 quote and the 2026 non-GAAP EPS guidance midpoint of about $4.95. The three-year framework produced a bullish area near $110 to $130, a base area near $78 to $92, and a bearish area near $42 to $55 before future dilution, larger deal effects, or major competitive shocks. Q2 2026 results on August 6, 2026 fall after the data cutoff.
$110 to $130
More likely if 2026 revenue lands near or above the $3.825 billion to $3.925 billion guidance range, Amicus products scale cleanly, VOXZOGO holds growth despite competition, non-GAAP EPS tracks the $4.85 to $5.05 guide, and investors re-rate the stock toward a higher forward multiple.
$78 to $92
More likely if revenue growth stays solid, Amicus adds scale but interest expense and integration costs limit multiple expansion, VOXZOGO growth moderates, and the market values BMRN closer to a low-teens non-GAAP earnings multiple.
$42 to $55
More likely if VOXZOGO faces faster competitive share loss, Amicus integration disappoints, leverage and interest costs compress free cash flow, payer pressure cuts net price, or the stock rerates toward a lower earnings multiple.
BMRN AI technical analysis
BMRN AI technical analysis is constructive but not breakout-confirmed as of the August 3, 2026 cutoff. The July 31, 2026 close near $60.02 sat above the rising 20, 50, 100, and 200-day moving averages, ChartMill rated the stock 7 out of 10 with layered support from about $57 up through $59.9, and the main upside cap remains the $63 area into the roughly $66.28 52-week high.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $60.02 | July 31, 2026 close used for research, market cap math, and scenario valuation as of the August 3, 2026 cutoff. |
| Near support | $59.68 to $59.92 | ChartMill listed a daily support zone formed by trend lines and moving averages near $59.68 to $59.92, with a stop-loss reference just below the zone. |
| Secondary support | $57.28 to $58.64 | ChartMill listed a multi-timeframe support zone near $57.28 to $58.64 that overlaps the rising 50-day and 100-day moving averages near $57.3 and $56.1. |
| Weekly support | $51.45 to $51.46 | ChartMill listed a weekly support area near $51.45, close to the $49.26 lower end of the 52-week range. |
| Moving averages | Constructive | The 20-day ($59.68), 50-day ($57.28), 100-day ($56.09), and 200-day ($56.29) moving averages are rising and the July 31, 2026 close was above all of them. |
| Resistance | $60.33 to $66.28 | ChartMill flagged weekly trend-line resistance near $60.33, with the next band around the $63.05 recent high and the $66.28 52-week high zone reported by market data sources. |
| Momentum | Neutral to positive | Daily RSI near 55 is neutral and the daily MACD sits slightly below zero, while the weekly MACD is above zero and rising and the weekly trend is up. |
| Volume | Event-sensitive biotech volume | Average volume has recently clustered near about 1.6 million to 2.0 million shares. Compare spikes with earnings, Amicus updates, VOXZOGO competitive news, and pipeline headlines. |
| Volatility | Elevated for a profitable rare-disease name | Daily ATR is about 2.5%. Expect larger moves around the August 6, 2026 Q2 report, Amicus integration metrics, VOXZOGO competition, and clinical or regulatory events. |
| Invalidation | Close below $57, then $51 | A decisive break below the $57 to $58 support zone would weaken the recovery setup. A break below about $51 would require a deeper thesis review of competition, leverage, and growth durability. |
BMRN AI trading strategy
The BMRN AI trading strategy is a rules-based framework for a profitable rare-disease biotech with product concentration, M&A integration risk, and event-driven volatility. It is not personal advice and should be paired with live quotes, filings, position sizing, and competitive or regulatory event checks.
Watch for BMRN to hold above the $57 to $60 support band, stay above the rising 20, 50, and 200-day moving averages, and advance toward the $63 to $66 resistance area with confirming volume and no negative VOXZOGO or Amicus headlines.
A close below $57 should invalidate the short-term recovery setup. A close below $51 should force a full review of competition, leverage, and earnings durability.
If BMRN pulls back toward the mid-$50s without a new competitive, integration, or payer problem, compare the price move with Enzyme Therapies growth, VOXZOGO demand, 2026 revenue guidance, and operating cash flow.
Do not treat every pullback as mean reversion. Rare-disease support levels can fail quickly when competitive share shifts or integration costs reset the earnings path.
Track Enzyme Therapies revenue, VOXZOGO patient starts and net sales, GALAFOLD and POMBILITI + OPFOLDA contribution, the August 6, 2026 Q2 report, 2026 total revenue and non-GAAP EPS guidance, operating cash flow, cash, debt, and interest expense after the Amicus financing.
Reduce confidence if the bull case depends mainly on multiple expansion rather than durable product growth, successful Amicus integration, and sustained free cash flow after higher leverage.
Investment research summary
BioMarin turns genetics, enzyme replacement, and rare-disease commercial execution into medicine revenue for patients with limited alternative treatments, charging payers and health systems for therapies that address serious genetic conditions.
The moat is strongest where orphan-drug IP, regulatory barriers, specialist trust, manufacturing capability, and multi-product rare-disease infrastructure reinforce each other. It narrows if rival achondroplasia or lysosomal therapies match efficacy, convenience, access, or net price.
The thesis fails if VOXZOGO growth slows faster than expected under Ascendis Yuviwel or BridgeBio competition, Amicus integration and debt costs dilute free cash flow, ROCTAVIAN remains economically weak, BMN 401 or other pipeline programs disappoint, or the earnings multiple compresses before growth re-accelerates.
Alexander Hardy and the team have focused the portfolio, improved operating leverage, and used M&A to expand the commercial base. The next test is disciplined Amicus integration, leverage management, and pipeline productivity after de-emphasizing lower-priority programs.
Rare-disease and genetic medicine remain long-duration growth categories, but adoption depends on durable outcomes, safety, access, manufacturing cost, and competition from small molecules, next-generation biologics, and other genetic approaches.
BMRN is no longer priced like a pure story biotech after the multi-year derating, and the forward non-GAAP earnings multiple of about 12x the 2026 guide looks less demanding than many growth biotech peers. Margin of safety improves if Amicus contributes as guided and VOXZOGO holds share; it shrinks if competition or leverage resets cash flow expectations.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| BMRN price | $60.02 July 31, 2026 close | StockAnalysis and ChartMill market snapshots | August 3, 2026 |
| Market capitalization | $11.60 billion, verified as $60.02 x 193.28 million shares | financial_rigor.py market cap verification and StockAnalysis | August 3, 2026 |
| Shares outstanding | 193.28 million | StockAnalysis share statistics and BioMarin Q1 2026 balance sheet | August 3, 2026 |
| FY2025 total revenues | $3.221 billion, up 13% year over year | BioMarin FY2025 earnings release and StockAnalysis financials | August 3, 2026 |
| FY2025 GAAP and non-GAAP diluted EPS | GAAP $1.80; non-GAAP $3.15 | BioMarin FY2025 earnings release and PR Newswire table | August 3, 2026 |
| FY2025 VOXZOGO and Enzyme Therapies revenue | VOXZOGO $927 million (+26% Y/Y); Enzyme Therapies $2.105 billion | BioMarin FY2025 earnings release product tables | August 3, 2026 |
| FY2025 free cash flow and operating cash flow | Free cash flow about $725 million (StockAnalysis and Macrotrends); operating cash flow $828 million (company) | StockAnalysis cash flow page and BioMarin FY2025 release | August 3, 2026 |
| Q1 2026 revenues and EPS | Total revenues $766 million; GAAP diluted EPS $0.54; non-GAAP diluted EPS $0.76; operating cash flow $221 million | BioMarin Q1 2026 earnings release | August 3, 2026 |
| Updated 2026 guidance after Amicus close | Total revenues $3.825B to $3.925B; Enzyme Therapies $2.725B to $2.775B; VOXZOGO $975M to $1,025M; non-GAAP diluted EPS $4.85 to $5.05 | BioMarin Q1 2026 guidance update after Amicus close on April 27, 2026 | August 3, 2026 |
| Amicus Therapeutics acquisition | All-cash deal at about $4.8 billion equity value; closed April 27, 2026; about $3.7 billion non-convertible financing secured | BioMarin and Amicus transaction announcements and close release | August 3, 2026 |
| Balance sheet and leverage | At March 31, 2026, cash and investments about $2.2 billion, long-term debt $1.430 billion, net cash about $792 million; post-close leverage to be clarified with Q2 2026 results | BioMarin Q1 2026 condensed balance sheet and StockAnalysis statistics | August 3, 2026 |
| Analyst consensus | Buy rating with a $87.92 average price target across 25 analysts, implying upside from $60.02 | StockAnalysis analyst forecast page | August 3, 2026 |
| Technical support and resistance | Support zones near $59.68 to $59.92 and $57.28 to $58.64; deeper support near $51.45; upside resistance toward $60.33, $63.05, and the $66.28 52-week high area | ChartMill technical analysis | August 3, 2026 |
This BMRN AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of August 3, 2026 and can be wrong if financial results, clinical data, regulation, competition, interest rates, integration outcomes, or market sentiment change. Q2 2026 results are scheduled for August 6, 2026, after this data cutoff.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
